Reducing Risk of Severe Liver Injury in Patients Treated With Isoniazid

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 9, 2015, Pages 1683-1685

  Andrade, Raúl J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HIGH RISK PATIENT; HUMAN; INJURY SEVERITY; LATENT TUBERCULOSIS; LIVER INJURY; LIVER TOXICITY; PHENOTYPE; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME; DRUG SURVEILLANCE PROGRAM; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH SERVICES RESEARCH; MALE; PRACTICE GUIDELINE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GUIDELINE ADHERENCE; HEALTH SERVICES RESEARCH; HUMANS; ISONIAZID; MALE;

EID: 84939568095     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.04.021     Document Type: Editorial

References (16)

1. Andrade R.J., Lucena M.I., Fernández M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
2. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Drug-Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 35:1924-1934.
3. Hayashi P.H., Fontana R.J., Chalasani N.P., et al. Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. Clin Gastroenterol Hepatol 2015, 13:1676-1682.
4. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010, 59:224-229.
5. Garibaldi R.A., Drusin R.E., Ferebee S.H., et al. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972, 106:357-365.
6. Devarbhavi H., Andrade R.J. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-Inflammatory drugs. Semin Liver Dis 2014, 34:145-161.
7. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
8. Reuben A., Koch D.G., Lee W.M. Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
9. Robles-Diaz M., Lucena M.I., Kaplowitz N., et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014, 147:109-118.
10. Fontana R.J., Hayashi P.H., Gu J., et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014, 147:96-108.
11. Sterling T.R., Bethel J., Goldberg S., et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006, 173:927-931.
12. Andrade R.J., Agúndez J.A., Lucena M.I., et al. Pharmacogenomics in drug-induced liver injury. Curr Drug Metab 2009, 10:956-970.
13. Huang Y.S., Chern H.D., Su W.J., et al. Polymorphism of the N acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002, 35:883-889.
14. Cai Y., Yi J., Zhou C., et al. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One 2012, 7:e47769.
15. Ng C.S., Hasnat A., Al Maruf A., et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol 2014, 70:1079-1086.
16. Azuma J., Ohno M., Kubota R., et al. Pharmacogenetics-based tuberculosis therapy research group. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013, 69:1091-1101.